

Participation aux publications

AXL Controls Directed Migration of Mesenchymal Triple-Negative Breast Cancer Cells. Olivier Zajac, Renaud Leclere, André Nicolas, Didier Meseure, Caterina Marchiò, Anne Vincent-Salomon, Sergio Roman-Roman, Marie Schoumacher and Thierry Dubois. *Cells* 2020.

Ligation-dependent RT-PCR: a new specific and low-cost technique to detect gene fusion in salivary gland tumors. Marie-Delphine Lanic, Michel Wassef, Didier Meseure, René Guérin, Anne-Catherine Baglin, Fabrice Jardin, Philippe Ruminy and Marick Laé. *USCAP congress* 2020.

Altered expression of three EGFR post-translational regulators MDG1, MIG6 and EIG121 in invasive breast carcinomas. Didier Meseure, Kinan Drak Alsibai, Sophie Vacher, Rana Hatem, Andre Nicolas, Celine Callens, Florence Lerebours, and Ivan Bieche. *Journal of Analytical Cellular Pathology* 2020.

Identification of two functionally distinct subsets of macrophages infiltrating human breast cancer. Rodrigo Nalio Ramos, Yoann Missolo Koussou, Nicolas Nuñez, Jimena Tosello, Wilfrid Richer, Yohan Gerber, Laetitia Lesage, André Nicolas, Didier Meseure, Anne Vincent-Salomon, Charles-Antoine Dutertre, Florent Ginhoux, Kristine Vaivode, Pierre Guermonprez, Eliane Piaggio, Julie Helft. *EMDS* 2019.

Image analysis of Tertiary Lymphoid Structures in human breast cancer. Faezeh Moazami, Laetitia Lesage, Lilith Faucheux et al. 2019.

Utilisation de longs ARN non codants pour le diagnostic urinaire du cancer de la prostate. Anna Almeida, Zohra Saci, Marina Pinskaya et al. April 2019 *Bulletin de l'Académie nationale de médecine* 203(3-4). DOI: 10.1016/j.banm.2018.03.001

Biopathological significance of deregulated PIWIL1-4 proteins belonging to the PIWI-piRNA pathway in invasive breast carcinomas. Didier meseure, Marick Lae, Kinan Drak Alsibai, Andre Nicolas, Sophie Vacher, Walid Chemlali, Yves Allory, Anne Vincent-Salomon and Ivan Bieche. *ECP congress* 2019.

Mechanotransduction in mice colon tumorigenesis: a pathologically reactivated physiological embryonic mechanosensitive pathway. Emmanuel farge and Didier Meseure. *ECP congress* 2019.

Centrosome amplification favours survival and impairs ovarian cancer progression. Jean-Philippe Morretton, Aurélie Herbette, Camille Cosson, Bassirou Mboup, Aurélien Latouche, Pierre Gestraud, Tatiana Popova, Marc-Henri Stern, Fariba Nemati, Didier Decaudin, Guillaume Bataillon, Véronique Becette, Didier Meseure, André Nicolas, Odette Mariani, Claire Bonneau, Jorge Barbazan, Anne Vincent-Salomon, Fatima Mechta-Grigoriou, Sergio Roman Roman, Roman Rouzier, Xavier Sastre-Garau, Oumou Goundiam and Renata Basto. *ORCID Profile preprint* 2019.

PLK1 as new target for metastatic ER positive breast cancers. Elodie Montaudon, Joanna Nikitorowicz-Buniak, Laura Sourd et al. *ASCO 2019*.

PARP Inhibition Increases the Response to Chemotherapy in Uveal Melanoma. de Koning L, Decaudin D, El Botty R, et al. *Cancers (Basel)* 2019;11:751.

Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer. Borcoman E, De La Rochere P, Richer W, et al. *Oncoimmunology* 2019;8(5):e1581556.

Immune gene expression in head and neck squamous cell carcinoma patients. Lecerf C, Kamal M, Vacher S, et al. Eur J Cancer 2019;121:210–223.

Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers. Vinet M, Suresh S, Maire V, Monchecourt C, Némati F, Lesage L, Pierre F, Ye M, Lescure A, Brisson A, Meseure D, Nicolas A, Rigaill G, Marangoni E, Del Nery E, Roman-Roman S, Dubois T. Cancer Med 2019;8:2414–2428.

High Positive Correlations between ANRIL and p16-CDKN2A/p15-CDKN2B/p14-ARF Gene Cluster Overexpression in Multi-Tumor Types Suggest Deregulated Activation of an ANRIL-ARF Bidirectional Promoter. Drak Alsibai K, Vacher S, Meseure D, et al. Noncoding RNA 2019;5:44.

Vasa nervorum angiogenesis in prostate cancer with perineural invasion. Ghinea N, Robin B, Pichon C, et al. Prostate 2019;79:640–646.

Anapath/IA, le choc des images. Arnaud Janin. DÉCISION & STRATÉGIE SANTÉ 2018 N°312 25-27

PKD1 is a potential biomarker and therapeutic target in triple-negative breast cancer. Spasojevic C, Marangoni E, Vacher S, Assayag F, Meseure D, Château-Joubert S, Humbert M, Karam M, Ricort JM, Auclair C, Regairaz M, Bièche I. Oncotarget 2018;9:23208–23219.

Hippocampal Sparing During Craniospinal Irradiation: What Did We Learn About the Incidence of Perihippocampus Metastases?. Padovani L, Chapon F, André N, et al. Int J Radiat Oncol Biol Phys 2018;100:980–986.

Replacement and desmoplastic histopathological growth patterns: A pilot study of prediction of outcome in patients with uveal melanoma liver metastases. Barnhill R, Vermeulen P, Daelemans S, et al. J Pathol Clin Res 2018;4:227–240.

Multi-stage pathological and immunohistochemical characterization of N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced murine bladder cancer. J. Fontugne J. WongN. Karboul October 2018 European Urology Supplements 17(10):e2488. DOI: 10.1016/S1569-9056(18)32973-7.

The PIWI-piRNA Pathway Is an Immune-Like Surveillance Process That Controls Genome Integrity by Silencing Transposable Elements. Didier Meseure and Kinan Drak Alsibai. December 2018.DOI: 10.5772/intechopen.79974 In book: Epigenetics. License CC BY 3.0.

Deregulated expressions of PIWI proteins and piRNAs as new candidate biomarkers and potential therapeutic tools in cancer. Didier Meseure and Kinan Drak Alsibai. December 2018.DOI: 10.5772/intechopen.79974 In book: Epigenetics. License CC BY 3.0.

Significance of Tumor Microenvironment Scoring and Immune Biomarkers in Patient Stratification and Cancer Outcomes. Didier Meseure and Kinan Drak Alsibai. September 2018. DOI: 10.5772/intechopen.72648. In book: Histopathology - An Update. LicenseCC BY 3.0.

High AHR expression in breast tumors correlates with expression of genes from several signaling pathways namely inflammation and endogenous tryptophan metabolism. Vacher S, Castagnet P, Chemlali W, Lallemand F, Meseure D, Pocard M, Bieche I, Perrot-Applanat M. PLoS One 2018;13:e0190619. doi: 10.1371/journal.pone.0190619.

Digital Image Analysis in Clinical and Experimental Pathology: An Ode to Microscopy. Book Title: Medical Image Processing for Improved Clinical Diagnosis. Meseure D; Drak Alsibai K. Edition: IGI Global 2018.

Anti-Müllerian hormone type II receptor (AMHRII) found expressed in human non-gynecological solid tumors, suggesting potential broader applications for anti-AMHRII-based therapy. Jean marc Barret, Didier Meseure, Guillaume Bataillon et al. AACR 2018.

Tumor microenvironment and noncoding RNAs as co-drivers of epithelialmesenchymal transition and cancer metastasis. Meseure D, Drak Alsibai K. Dev Dyn 2017. doi: 10.1002/dvdy.24548.

Clinical value of R-spondins in triple-negative and metaplastic breast cancers. Coussy F, Lallemand F, Vacher S, Schnitzler A, Chemlali W, Caly M, Nicolas A, Richon S, Meseure D, El Botty R, De-Plater L, Fuhrmann L, Dubois T, Roman-Roman S, Dangles-Marie V, Marangoni E, Bièche I. Br J Cancer 2017;116:1595-1603.

L'imagerie moléculaire vue par le pathologiste. Jérôme Cros, Hôpital Beaujon, Paris et Didier Meseure, Institut Curie, Paris. Session Imagerie Moléculaire: du Macro au Microscopique. Carrefour de Pathologie 2017

Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer. Mameri H, Bièche I, Meseure D, Marangoni E, Buhagiar-Labarchède G, Nicolas A, Vacher S, Onclercq-Delic R, Rajapakse V, Varma S, Reinhold WC, Pommier Y, Amor-Guéret M. Clin Cancer Res 2017;23:2116-2126.

Contribution of germline deleterious variants in the RAD51 paralogs to breast and ovarian cancers. Golmard L, Castéra L, Krieger S, et al. Eur J Hum Genet 2017;25:1345–1353.

The humanized anti-human AMHRII mAb 3C23K exerts an anti-tumor activity against human ovarian cancer through tumor-associated macrophages. Bougerara H, Némati F, Nicolas A, Massonet G, Pugnière M, Ngô C, Le Frère-Belda MA, Leary A, Alexandre J, Meseure D, Barret JM, Navarro-Teulon I, Pèlegrin A, Roman-Roman S, Prost JF, Donnadieu E, Decaudin D. Oncotarget 2017;8:99950-99965.

The occurrence of intracranial rhabdoid tumours in mice depends on temporal control of Smarcb1 inactivation. Han ZY, Richer W, Fréneaux P, Chauvin C, Lucchesi C, Guillemot D, Grison C, Lequin D, Pierron G, Masliah-Planchon J, Nicolas A, 2014 - 2018 Page 2 sur 3 Ranchère-Vince D, Varlet P, Puget S, Janoueix-Lerosey I, Ayrault O, Surdez D, Delattre O, Bourdeaut F. Nat Commun 2016;7:10421. doi: 10.1038/ncomms10421.

Biopathological Significance of TLR9 Expression in Cancer Cells and Tumor Microenvironment Across Invasive Breast Carcinomas Subtypes. Meseure D, Vacher S, Drak Alsibai K, Trassard M, Nicolas A, Leclerc R, Lerebours F, Guinebretiere JM, Marangoni E, Lidereau R, Bieche I. Cancer Microenviron 2016;9:107-118.

Protein arginine methyltransferase 1 (PRMT1) is a candidate therapeutic target for breast cancers. David Sylvestre, Amélie Brisson, Bérengère Marty et al. AACR, Cancer Research 76(14 Supplement):3809-3809.

Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigen. Sedlik C, Heitzmann A, Viel S, et al. Oncoimmunology 2016;5(7):e1171434. doi:10.1080/2162402X.2016.1171434.

Prognostic value of a newly identified *MALAT1* alternatively spliced transcript in breast Cancer. Meseure D, Vacher S, Lallemand F, Alsibai KD, Hatem R, Chemlali W, Nicolas A, De Koning L, Pasman E, Callens C, Lidereau R, Morillon A, Bieche I. Br J Cancer 2016.

Expression of ANRIL-Polycomb Complexes-CDKN2A/B/ARF Genes in Breast Tumors: Identification of a Two-gene (*EZH2/CBX7*) Signature with Independent Prognostic Value. Meseure D, Vacher S, Drak Alsibai K, Nicolas A, Chemlali W, Caly M, Lidereau R, Pasman E, Callens C, Bieche I. Mol Cancer Res 2016.

Cytokine and Chemokine Expression in Kidneys during Chronic Leptospirosis in Reservoir and Susceptible Animal Models. Matsui M, Roche L, Geroult S, SoupéGilbert ME, Monchy D, Huerre M, Goarant C. PLoS One 2016;11(5):e0156084.

Assessment of EGFR-dependent signaling pathway targeting in EGFR-mutated and wild type non-small cell lung cancer patient-derived xenografts. 2016. DOI: 10.1016/S0959-8049(16)32986-32998.

Ligand-receptor dissociated expression explains high TSLP without prognostic impact in human primary head and neck squamous cell carcinoma. Guillot-Delost M, Guilleré L, Berger F, et al. Oncoimmunology 2016;5(7):e1179414. doi:10.1080/2162402X.2016.1179414.

No evidence for TSLP pathway activity in human breast cancer. Ghirelli C, Sadacca B, Reyal F, et al. Oncoimmunology 2016;5(8):e1178438. doi:10.1080/2162402X.2016.1178438.

Characterization of Breast Cancer Preclinical Models Reveals a Specific Pattern of Macrophage Polarization. Vallerand D, Massonet G, Kébir F, Gentien D, Maciorowski Z, De la Grange P, Sigal-Zafrani B, Richardson M, Humbert S, Thuleau A, Assayag F, de Plater L, Nicolas A, Scholl S, Marangoni E, Weigand S, RomanRoman S, Savina A, Decaudin D. PLoS One 2016;11:e0157670.

Colorectal cancer metastasis: the DNA repair inhibitor Dbait increases sensitivity to hyperthermia and improves efficacy of radiofrequency ablation. Devun F, Biau J, Huerre M, Croset A, Sun JS, Denys A, Dutreix M. Radiology 2014;270:736-46.

Long Noncoding RNAs as New Architects in Cancer Epigenetics, Prognostic Biomarkers, and Potential Therapeutic Targets. Meseure D, Drak Alsibai K, Nicolas A, Bieche I, Morillon A. Biomed Res Int. 2015;2015:320214. doi: 10.1155/2015/320214.

TIPIN depletion leads to apoptosis in breast cancer cells. Baldeyron C, Brisson A, Tesson B, Némati F, Koundrioukoff S, Saliba E, De Koning L, Martel E, Ye M, Rigaill G, Meseure D, Nicolas A, Gentien D, Decaudin D, Debatisse M, Depil S, Cruzalegui F, Pierré A, Roman-Roman S, Tucker GC, Dubois T. Mol Oncol 2015;9:1580-98.

Evaluating patient-derived colorectal cancer xenografts as preclinical models by comparison with patient clinical data. Nunes M, Vrignaud P, Vacher S, Richon S, Lièvre A, Cacheux W, Weiswald LB, Massonet G, Chateau-Joubert S, Nicolas A, Dib C, Zhang W, Watters J, Bergstrom D, Roman-Roman S, Bièche I, Dangles-Marie V. Cancer Res 2015;75:1560-6.

Alternatively spliced MALAT1 transcripts are independent prognostic factors in human breast cancer. Meseure D, Vacher S, Lallemand F, Alsibai KD et al. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin 2015; 467:S53-S53.

HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts. de Cremoux P, Dalvai M, N'Doye O, Moutahir F, Rolland G, Chouchane-Mlik O, Assayag F, Lehmann-Che J, KrausBerthie L, Nicolas A, Lockhart BP, Marangoni E, de Thé H, Depil S, Bystricky K, Decaudin D. Breast Cancer Res Treat 2015;149:81-9.

Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesis. Wassef M, Rodilla V, Teissandier A, Zeitouni B, Gruel N, Sadacca B, Irondelle M, Charruel M, Ducos B, Michaud A, Caron M, Marangoni E, Chavrier P, Le Tourneau C, Kamal M, Pasmant E, Vidaud M, Servant N, Reyal F, Meseure D, Vincent-Salomon A, Fre S, Margueron R. Genes Dev 2015;29:2547-62.

Hyperactivation of Alk induces neonatal lethality in knock-in AlkF1178L mice. LopezDelisle L, Pierre-Eugène C, Bloch-Gallego E, Birling MC, Duband JL, Durand E, Bourgeois T, Matrot B, Sorg T, Huerre M, Meziane H, Roux MJ, Champy MF, Gallego J, Delattre O, Janoueix-Lerosey I. Oncotarget. 2014;5:2703-13.

Pivotal role of pervasive neoplastic and stromal cells reprogramming in circulating tumor cells dissemination and metastatic colonization. Meseure D, Drak Alsibai K, Nicolas A. Cancer Microenviron 2014;7:95-115.

The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma. Montes de Oca R, Gurard-Levin ZA, Berger F, Rehman H, Martel E, Corpet A, de Koning L, Vassias I, Wilson LO, Meseure D, Reyal F, Savignoni A, Asselain B, Sastre-Garau X, Almouzni G. Mol Oncol 2015;9:657-74.

In vivo synergism between chemotherapy and the 3C23K monoclonal antibody targeting the AMH-type II receptor in ovarian cancer PDX models. March Annals of Oncology 2015. 26(suppl 2):ii23DOI: 10.1093.

Evaluating patient-derived colorectal cancer xenografts as preclinical models by comparison with patient clinical data. Nunes M, Vrignaud P, Vacher S, et al. Cancer Res 2015;75:1560–1566.

Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target. Amirouchene Angelozzi N, Nemati F, Gentien D, Nicolas A, Dumont A, Carita G, Camonis J, Desjardins L, Cassoux N, Piperno-Neumann S, Mariani P, Sastre X, Decaudin D, Roman-Roman S. Mol Oncol 2014;8:1508-20.

Concomitant Notch activation and p53 deletion trigger epithelial-to-mesenchymal transition and metastasis in mouse gut. Chanrion M, Kuperstein I, Barrière C, El Marjou F, Cohen D, Vignjevic D, Stimmer L, Paul-Gilloteaux P, Bièche I, Tavares Sdos R, Boccia GF, Cacheux W, Meseure D, Fre S, Martignetti L, Legoix-Né P, Girard E, Fetler L, Barillot E, Louvard D, Zinovyev A, Robine S. Nat Commun 2014;5:5005. doi: 10.1038/ncomms6005.

Cancer Metabolic and Immune Reprogramming: The Intimate Interaction Between Cancer Cells and Microenvironment. Didier Meseure and Kinan Drak Alsibai. J Cancer Prev Curr Res 2014, 1(2): 00006.

Didier Meseure, Kinan Drak AlsibaiTubulin glycylases are required for primary cilia, control of cell proliferation and tumor development in colon. Rocha C, Papon L, Cacheux W, Marques Sousa P, Lascano V, Tort O, Giordano T, Vacher S, Lemmers B, Mariani P, Meseure D, Medema JP, Bièche I, Hahne M, Janke C. EMBO 2014;33:2247-60.

Predictive gene signature of response to the anti-TweakR mAb PDL192 in patient-derived breast cancer xenografts. de Plater L, Vincent-Salomon A, Berger F, et al. PLoS One 2014;9(11):e104227. doi:10.1371/journal.pone.0104227.

PIK3R1 underexpression is an independent prognostic marker in breast cancer. Cizkova M, Vacher S, Meseure D, et al. BMC Cancer 2013;13:545.

Germline mutation in the RAD51B gene confers predisposition to breast cancer. Golmard L, Caux-Moncoutier V, Davy G, et al. BMC Cancer 2013;13:484-484.

Germline BAP1 mutations predispose to renal cell carcinomas. Popova T, Hebert L, Jacquemin V, et al. Am J Hum Genet 2013;92:974–980.

Patient-derived xenografts recapitulate molecular features of human uveal melanomas. Laurent C, Gentien D, Piperno-Neumann S, et al. Mol Oncol 2013;7:625–636.

New blocking antibodies impede adhesion, migration and survival of ovarian cancer cells, highlighting MFGE8 as a potential therapeutic target of human ovarian carcinoma. Tibaldi L, Leyman S, Nicolas A, et al. PLoS One 2013;8(8):e72708. doi:10.1371/journal.pone.0072708.

Profiling of EGFR mRNA and protein expression in 471 breast cancers compared with 10 normal tissues: a candidate biomarker to predict EGFR inhibitor effectiveness. Meseure D, Vacher S, Drak Alsibai K, et al. Int J Cancer 2012;131:1009–1010.

Persistent lung oscillator response to CO₂ after buccal oscillator inhibition in the adult frog. Leclère R, Straus C, Similowski T, Bodineau L, Fiamma MN. Respir Physiol Neurobiol 2012;183:166–169.

Polycomb Genes and Large Non Coding RNAs Expressions in Invasive Breast Carcinomas: New Clues for Epigenetic Targeted Therapies. Didier Meseure, Kinan Drak Alsibai, M. Trassard et al. Laboratory Investigation 2012.

Identification of new candidate therapeutic target genes in triple-negative breast cancer. Glénisson M, Vacher S, Callens C, et al. Genes Cancer 2012;3:63–70.

Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy. Hubert P, Heitzmann A, Viel S, et al. Cancer Res 2011;71:5134–5143.

Role of the focal adhesion protein kindlin-1 in breast cancer growth and lung metastasis. Sin S, Bonin F, Petit V, et al. J Natl Cancer Inst 2011;103:1323–1337.

miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Mateescu B, Batista L, Cardon M, et al. Nat Med 2011;17:1627–1635.

A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer. Meyniel JP, Cottu PH, Decraene C, et al. BMC Cancer 2010;10:222.

Ligation-dependent RT-PCR: a new specific and low-cost technique to detect gene fusion in salivary gland tumors. Marie-Delphine Lanic, Michel Wassef, Didier Meseure, René Guérin, Anne-Catherine Baglin, Fabrice Jardin, Philippe Ruminy and Marick Laé. USCAP congress 2020.

Tumor invasion in draining lymph nodes is associated with Treg accumulation in breast cancer patients. Núñez NG, Tosello Boari J, Ramos RN, Richer W, Cagnard N, Anderfuhren CD, Niborski LL, Bigot J, Meseure D, De La Rochere P, Milder M, Viel S, Loirat D, Pérol L, Vincent-Salomon A, Sastre-Garau X, Burkhard B, Sedlik C, Lantz O, Amigorena S, Piaggio E. Nat Commun. 2020 Jun 29;11(1):3272. doi: 10.1038/s41467-020-17046-2. PMID: 32601304; PMCID: PMC7324591.

PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance. Montaudon E, Nikitorowicz-Buniak J, Sourd L, Morisset L, El Botty R, Huguet L, Dahmani A, Painsec P, Nemati F, Vacher S, Chemlali W, Masliah-Planchon J, Château-Joubert S, Rega C, Leal MF, Simigdala N, Pancholi S, Ribas R, Nicolas A, Meseure D, Vincent-Salomon A, Reyes C, Rapinat A, Gentien D, Larcher T, Bohec M, Baulande S, Bernard V, Decaudin D, Coussy F, Le Romancer M, Dutertre G, Tariq Z, Cottu P, Driouch K, Bièche I, Martin LA, Marangoni E. Nat Commun. 2020 Aug 13;11(1):4053. doi: 10.1038/s41467-020-17697-1. PMID: 32792481; PMCID: PMC7426966.

Biopathological Significance of PIWI-piRNA Pathway Dereulation in Invasive Breast Carcinomas. Meseure D, Vacher S, Boudjemaa S, Laé M, Nicolas A, Leclerc R, Chemlali W, Champenois G, Schnitzler A, Lesage L, Dubois T, Bieche I. Cancers (Basel). 2020 Sep 30;12(10):2833. doi: 10.3390/cancers12102833. PMID: 33008024; PMCID: PMC7600338.

Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. Floris G, Richard F, Hamy AS, Jongen L, Wildiers H, Ardui J, Punie K, Smeets A, Berteloot P, Vergote I, De Croze D, Meseure D, Salomon A, Laé M, Reyal F, Biganzoli E, Neven P, Desmedt C. J Natl Cancer Inst. 2021 Feb 1;113(2):146-153. doi: 10.1093/jnci/djaa090. PMID: 33152071; PMCID: PMC7850533.

Grandal B, Mangiardi-Veltin M, Laas E, Laé M, Meseure D, Bataillon G, El-Alam E, Darrigues L, Dumas E, Daoud E, Vincent-Salomon A, Talagrand LS, Pierga JY, Reyal F, Hamy AS. PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy. Cancers (Basel). 2021 Feb 11;13(4):746. doi: 10.3390/cancers13040746. PMID: 33670162; PMCID: PMC7916886.